Literature DB >> 19673125

[Administration of afala preparation in urological practice].

A I Neĭmark, V I Isaenko, Ia V Iakovets, A V Simashkevich, R T Aliev.   

Abstract

Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination. Effect of this drug is seen in 98.3% patients during 4 weeks of its use. In longer intake the effect becomes stronger. The dose of 6 tablets a day significantly improves life quality. Three times a day dose is more effective in elimination of nicturia, enhances urine flow rate. Thus, choice of afala dose depends on the symptoms. Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673125

Source DB:  PubMed          Journal:  Urologiia        ISSN: 1728-2985


  1 in total

1.  Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial.

Authors:  Dmitry Pushkar; Andrey Vinarov; Leonid Spivak; Konstantin Kolontarev; Mikhail Putilovskiy; Elena Andrianova; Oleg Epstein
Journal:  Cent European J Urol       Date:  2018-12-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.